Don't want emails from us anymore? Click here to unsubscribe.
Hello!
CERO, our newest alert, released breaking news this morning that could be another positive growth catalyst for the company.
Here is the announcement from this morning:
"CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia"
"SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that TriStar Centennial Medical Center, through Sarah Cannon Research Institute (SCRI), in Nashville, Tennessee, is a clinical trial site for the Company's Phase 1 clinical of CER-1236. Collaborating with SCRI to advance cancer research, TriStar Centennial offers innovative clinical research trials for various disease indications. The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025."
As the company further explains:
"The first-in-human, multi-center, open label, Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed/refractory, has measurable residual disease, or has a mutation of the TP53 gene."
"The two-part study will begin with dose escalation to determine highest tolerated dose and recommended dose for Phase 2, followed by an expansion phase to evaluate safety and efficacy. Primary outcome measures include incidence of adverse events (AEs) and serious adverse events (SAEs), incidence of dose limited toxicities and estimation of overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD). Secondary outcome measures include pharmacokinetics (PK)."
Here are some of the company's comments from this press release:
"Stephen Strickland, Jr., M.D., MSCI, Director of Leukemia Research for SCRI, an investigator on the trial, commented, "In preclinical studies, CER-1236 was demonstrated to have a multifunctional approach to killing cancer cells, without sacrificing healthy cells. We believe that this novel mechanism of action may have significant impact on the way we treat cancer and are looking forward to participating in the clinical studies to investigate that possibility.""
In addition:
"Chris Ehrlich, CERo Therapeutics CEO added, "The rapid uptake of clinical trial site partners is a testament to both the scientific work performed to date with CER-1236 and the dedication and acumen of the teams at CERO and the research institutions where the trial will be conducted. It is well known that the assignment of clinical trial sites is a central milestone, and the prestige TriStar Centennial Medical Center, through SCRI, brings to the trial cannot be over-emphasized. We look forward to announcing enrollment and initial dosing in the near term.""
Following our alert this morning, CERO opened today just under 0.92 and has so far rallied to a high of 0.94.
CERO has a 50 day moving average of 1.05, more than 14% above today's open.
A breakout and close above this level could present increased upside.
We are continuing to monitor this opportunity.
Sources: PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, PR9, PR10, PR11, Website, Chart
Happy Trading!
UltimateStockAlerts
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
